SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.

doi:10.1136/jitc-2020-001496

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.

Journal for immunotherapy of cancer - 1 Mar 2021

Redin Esther, Garmendia Irati, Lozano Teresa, Serrano Diego, Senent Yaiza, Redrado Miriam, Villalba Maria, De Andrea Carlos E, Exposito Francisco, Ajona Daniel, Ortiz-Espinosa Sergio, Remirez Ana, Bertolo Cristina, Sainz Cristina, Garcia-Pedrero Juana, Pio Ruben, Lasarte Juan, Agorreta Jackeline, Montuenga Luis M, Calvo Alfonso

Abstract excerpt

INTRODUCTION: The use of immune-checkpoint inhibitors has drastically improved the management of patients with non-small cell lung cancer (NSCLC), but innate and acquired resistances are hurdles needed to be solved. Immunomodulatory drugs that can reinvigorate the immune cytotoxic activity, in combination with antiprogrammed cell death 1 (PD-1) antibody, are a great promise to overcome resistance. We evaluated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dasatinib

Share to Immune Checkpoint Inhibitors

Share to Lymphocytes, Tumor-Infiltrating

Share to Mice, 129 Strain

Share to Programmed Cell Death 1 Receptor

Share to T-Lymphocytes, Regulatory

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 33658304
DOI: 10.1136/jitc-2020-001496
PMCID: PMC7931761

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.PMID 33658304Read ↗

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapySemantic proximity Read ↗

Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung CancerSemantic proximity Read ↗

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations.Semantic proximity Read ↗

Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma.Semantic proximity Read ↗

Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So FarSemantic proximity Read ↗

A Novel Bispecific Antibody Targeting Frizzled7 and PD-L1 Reverses Immunotherapy Resistance in Non-Small Cell Lung Cancer by Reprogramming the Tumor MicroenvironmentSemantic proximity Read ↗

The immunomodulatory properties of the HDAC6 inhibitor ACY241 supports robust anti-tumor response in NSCLC when coupled with the chemotherapy drug OxaliplatinSemantic proximity Read ↗

SRC: A Century of Science Brought to the ClinicSemantic proximity Read ↗

Exploring the potential value of SRC genes in pan cancer based on bioinformatics methodsSemantic proximity Read ↗

Autologous Cytokine-Induced Killer (CIK) Cell Immunotherapy plus Sintilimab and Chemotherapy in Advanced Non‒Small-Cell Lung Cancer: 3-Year Outcomes From the Phase Ib CCICC-002a StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.